Self-reported sleep variables, sleep quality, and quality of life assessment in transition to lemborexant in patients with Insomnia: the multicenter, open-label SOMNUS study

Aims: Lemborexant, a dual orexin receptor antagonist, is approved for treating adults with insomnia. We present diary-based sleep parameters, self-reported sleep quality, insomnia severity, and health-related quality of life following direct transition to lemborexant from previous treatment in Japan...

Full description

Bibliographic Details

Published in:	Sleep Medicine: X
Main Authors:	Motohiro Ozone, Susumu Hirota, Yu Ariyoshi, Kenichi Hayashida, Azusa Ikegami, Mitsunari Habukawa, Hayato Ohshima, Daisuke Harada, Hiroshi Hiejima, Nozomu Kotorii, Kenta Murotani, Yurie Nishi, Michinori Koebis, Takehiro Taninaga, Naohisa Uchimura
Format:	Article
Language:	English
Published:	Elsevier 2025-12-01
Subjects:	Sleep quality Health-related quality of life Insomnia Lemborexant Ramelteon Suvorexant
Online Access:	http://www.sciencedirect.com/science/article/pii/S2590142725000126